Newsroom Articles

Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.

2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.

Through their stories, families, advocates and experts paint a vivid picture of what life with Angelman syndrome looks like – the obstacles, the triumphs and the moments of strength that define their journeys. They share their experiences navigating the path to diagnosis, the hallmark signs and symptoms of AS and, most importantly, the incredible joy that their children with AS bring to their lives. 

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

Ionis is proud to announce that we have ranked #6 on the San Diego Business Journal’s 2025 Best Places to Work list in the Large Companies category. This marks our second consecutive year being recognized and our first year breaking into the Top 10…

Ionis CEO Brett Monia, Ph.D. shares the journey to becoming a fully integrated biotech, advancing RNA-targeted medicines and delivering greater impact for patients.